Stockreport

iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024 [Yahoo! Finance]

iTeos Therapeutics, Inc.  (ITOS) 
PDF company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced a poster presentation of preclinical d [Read more]